MX2017003066A - Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. - Google Patents
Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.Info
- Publication number
- MX2017003066A MX2017003066A MX2017003066A MX2017003066A MX2017003066A MX 2017003066 A MX2017003066 A MX 2017003066A MX 2017003066 A MX2017003066 A MX 2017003066A MX 2017003066 A MX2017003066 A MX 2017003066A MX 2017003066 A MX2017003066 A MX 2017003066A
- Authority
- MX
- Mexico
- Prior art keywords
- dementia
- quinidine
- agitation
- treatment
- pharmaceutical compositions
- Prior art date
Links
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 title abstract 4
- 206010012289 Dementia Diseases 0.000 title abstract 3
- 238000013019 agitation Methods 0.000 title abstract 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001985 dextromethorphan Drugs 0.000 title abstract 2
- -1 dextromethorphan compound Chemical class 0.000 title abstract 2
- 229960001404 quinidine Drugs 0.000 title abstract 2
- 206010001497 Agitation Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 230000016571 aggressive behavior Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050170P | 2014-09-14 | 2014-09-14 | |
| US201462061451P | 2014-10-08 | 2014-10-08 | |
| US201462063122P | 2014-10-13 | 2014-10-13 | |
| US201462063861P | 2014-10-14 | 2014-10-14 | |
| US201462068742P | 2014-10-26 | 2014-10-26 | |
| US201562111053P | 2015-02-02 | 2015-02-02 | |
| US201562111590P | 2015-02-03 | 2015-02-03 | |
| US201562128446P | 2015-03-04 | 2015-03-04 | |
| US201562162140P | 2015-05-15 | 2015-05-15 | |
| US201562165535P | 2015-05-22 | 2015-05-22 | |
| US201562169997P | 2015-06-02 | 2015-06-02 | |
| US201562180026P | 2015-06-15 | 2015-06-15 | |
| US201562193347P | 2015-07-16 | 2015-07-16 | |
| US201562205061P | 2015-08-14 | 2015-08-14 | |
| US201562216636P | 2015-09-10 | 2015-09-10 | |
| US201562217470P | 2015-09-11 | 2015-09-11 | |
| US201562217142P | 2015-09-11 | 2015-09-11 | |
| PCT/US2015/049934 WO2016040930A1 (en) | 2014-09-14 | 2015-09-14 | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003066A true MX2017003066A (es) | 2017-09-12 |
Family
ID=55459653
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003066A MX2017003066A (es) | 2014-09-14 | 2015-09-14 | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. |
| MX2022008181A MX2022008181A (es) | 2014-09-14 | 2017-03-08 | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. |
| MX2021010696A MX2021010696A (es) | 2014-09-14 | 2017-03-08 | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008181A MX2022008181A (es) | 2014-09-14 | 2017-03-08 | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. |
| MX2021010696A MX2021010696A (es) | 2014-09-14 | 2017-03-08 | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190111047A1 (enExample) |
| EP (4) | EP3932907A3 (enExample) |
| JP (4) | JP2017531033A (enExample) |
| KR (1) | KR20170052684A (enExample) |
| CN (3) | CN110664801A (enExample) |
| AU (3) | AU2015314710A1 (enExample) |
| CA (1) | CA2960031A1 (enExample) |
| IL (2) | IL250786A0 (enExample) |
| MX (3) | MX2017003066A (enExample) |
| MY (1) | MY198587A (enExample) |
| PH (1) | PH12017500444A1 (enExample) |
| RU (1) | RU2017112747A (enExample) |
| SG (2) | SG11201701645WA (enExample) |
| TW (3) | TW202106301A (enExample) |
| WO (1) | WO2016040930A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2792662T (pt) | 2007-05-01 | 2016-07-07 | Concert Pharmaceuticals Inc | Compostos de morfinano |
| WO2017020002A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| CA2994153A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| US10730841B2 (en) | 2016-07-04 | 2020-08-04 | Avanir Pharmaceuticals, Inc. | Methods for the synthesis of deuterated dextromethorphan |
| US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| CA3062452C (en) * | 2017-05-04 | 2023-10-24 | Exciva GmbH | Compositions, combinations, and methods thereof for treatment of neurological disorders |
| CA3100897A1 (en) * | 2018-05-18 | 2019-11-21 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| MY201603A (en) * | 2019-01-07 | 2024-03-05 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| WO2020190971A1 (en) * | 2019-03-18 | 2020-09-24 | Avanir Pharmaceuticals, Inc. | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine |
| IL296977A (en) * | 2020-04-27 | 2022-12-01 | Avanir Pharmaceuticals Inc | Methods of treating agitation associated with alzheimer's disease |
| WO2022228363A1 (zh) * | 2021-04-27 | 2022-11-03 | 杭州剂泰医药科技有限责任公司 | 一种组合物的医药用途 |
| CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
| CN113209042A (zh) * | 2021-05-28 | 2021-08-06 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法 |
| KR20240110812A (ko) * | 2021-10-27 | 2024-07-16 | 아바니르 파마슈티컬스, 인코포레이티드 | 알츠하이머병과 관련된 불안을 치료하는 방법 |
| CN116459255A (zh) * | 2022-01-19 | 2023-07-21 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬与安非他酮联合在制备ad激越的药物中的用途 |
| US11730706B1 (en) * | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| KR20250120917A (ko) | 2024-02-02 | 2025-08-11 | 단국대학교 천안캠퍼스 산학협력단 | 덱스트로메토르판을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물 |
| KR20250129211A (ko) | 2024-02-22 | 2025-08-29 | 단국대학교 천안캠퍼스 산학협력단 | 데가렐릭스를 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| US5366980A (en) | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| TW264473B (enExample) * | 1993-01-06 | 1995-12-01 | Hoffmann La Roche | |
| JP4097285B2 (ja) * | 1994-09-22 | 2008-06-11 | リチャード・アラン・スミス | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| MXPA00004919A (es) | 1997-11-21 | 2002-10-17 | Euro Celtique Sa | 2-aminoacetamidas sustituidas y uso de las mismas. |
| WO1999050245A1 (en) | 1998-03-26 | 1999-10-07 | Shionogi & Co., Ltd. | Indole derivatives with antiviral activity |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| CA2641392A1 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| WO2007103474A2 (en) * | 2006-03-07 | 2007-09-13 | University Of Florida Research Foundation, Inc. | Drug adherence monitoring system |
| WO2008097924A2 (en) * | 2007-02-05 | 2008-08-14 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |
| PT2792662T (pt) * | 2007-05-01 | 2016-07-07 | Concert Pharmaceuticals Inc | Compostos de morfinano |
| PT2152709E (pt) | 2007-05-01 | 2012-11-28 | Concert Pharmaceuticals Inc | Compostos de morfinano |
| CA2737811C (en) * | 2008-09-19 | 2019-07-09 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| EP2397158B1 (en) * | 2008-10-30 | 2016-04-13 | Concert Pharmaceuticals, Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect |
| ES2444433T3 (es) * | 2008-11-14 | 2014-02-25 | Concert Pharmaceuticals, Inc. | Derivados de dioxopiperidinil-ftalimida sustituidos |
| CN110327338A (zh) * | 2013-11-05 | 2019-10-15 | 安泰赛普生物风投二代有限责任公司 | 包含安非他酮或相关化合物和右美沙芬的组合物和方法 |
-
2015
- 2015-09-14 WO PCT/US2015/049934 patent/WO2016040930A1/en not_active Ceased
- 2015-09-14 TW TW109114123A patent/TW202106301A/zh unknown
- 2015-09-14 AU AU2015314710A patent/AU2015314710A1/en not_active Abandoned
- 2015-09-14 TW TW104130311A patent/TW201613591A/zh unknown
- 2015-09-14 CN CN201910903770.XA patent/CN110664801A/zh active Pending
- 2015-09-14 TW TW110139834A patent/TWI869633B/zh active
- 2015-09-14 CN CN202311175974.9A patent/CN117427077A/zh active Pending
- 2015-09-14 SG SG11201701645WA patent/SG11201701645WA/en unknown
- 2015-09-14 MX MX2017003066A patent/MX2017003066A/es unknown
- 2015-09-14 RU RU2017112747A patent/RU2017112747A/ru not_active Application Discontinuation
- 2015-09-14 US US15/510,498 patent/US20190111047A1/en not_active Abandoned
- 2015-09-14 JP JP2017533726A patent/JP2017531033A/ja active Pending
- 2015-09-14 EP EP21178170.3A patent/EP3932907A3/en not_active Withdrawn
- 2015-09-14 CA CA2960031A patent/CA2960031A1/en active Pending
- 2015-09-14 CN CN201580049454.0A patent/CN107072990A/zh active Pending
- 2015-09-14 EP EP20159783.8A patent/EP3708168A3/en not_active Withdrawn
- 2015-09-14 KR KR1020177009991A patent/KR20170052684A/ko not_active Ceased
- 2015-09-14 MY MYPI2017000321A patent/MY198587A/en unknown
- 2015-09-14 SG SG10201901242PA patent/SG10201901242PA/en unknown
- 2015-09-14 EP EP15840718.9A patent/EP3193872A4/en not_active Withdrawn
- 2015-09-14 EP EP22195837.4A patent/EP4166141A1/en not_active Withdrawn
-
2017
- 2017-02-26 IL IL250786A patent/IL250786A0/en unknown
- 2017-03-08 MX MX2022008181A patent/MX2022008181A/es unknown
- 2017-03-08 MX MX2021010696A patent/MX2021010696A/es unknown
- 2017-03-09 PH PH12017500444A patent/PH12017500444A1/en unknown
-
2019
- 2019-10-08 US US16/596,236 patent/US20200289499A1/en not_active Abandoned
- 2019-11-06 JP JP2019201410A patent/JP2020019818A/ja not_active Withdrawn
-
2020
- 2020-05-18 IL IL274742A patent/IL274742A/en unknown
- 2020-12-15 AU AU2020289733A patent/AU2020289733A1/en not_active Abandoned
-
2021
- 2021-03-08 JP JP2021036318A patent/JP7360409B2/ja active Active
-
2022
- 2022-12-06 AU AU2022283671A patent/AU2022283671B2/en not_active Expired - Fee Related
-
2023
- 2023-04-24 US US18/305,589 patent/US20240082237A1/en not_active Abandoned
- 2023-06-12 JP JP2023096152A patent/JP2023105265A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| MX2024010140A (es) | Nuevos metodos. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201791993A1 (ru) | Способы лечения протеинопатий | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| IN2015DN00376A (enExample) | ||
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| MY179105A (en) | Methods of treating alzheimer's disease | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| ZA201704327B (en) | Methods and compositions for treating brain diseases | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| SG10201809280PA (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| EA201892675A1 (ru) | Фармацевтическая композиция, содержащая этеплирсен | |
| MA37957A1 (fr) | Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées | |
| PL409386A1 (pl) | Preparaty peptydowe do zastosowania jako środek farmaceutyczny lub dodatek do żywności w zapobieganiu i leczeniu chorób neurodegeneracyjnych | |
| AR103764A1 (es) | Pridopidina como mejoradora de la función cognitiva y en el tratamiento de la enfermedad de alzheimer | |
| UA111587C2 (uk) | Сполуки для лікування захворювань, пов'язаних з амілоїдними або амілоїдоподібними білками |